Carcinoembryonic Antigen, CEA
545

Information

The ARCHITECT CEA assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of Carcinoembryonic Antigen (CEA) in human serum and plasma.

Increased serum CEA levels have been detected in persons with primary colorectal cancer and in patients with other malignancies involving the gastrointestinal tract, breast, lung, ovarian, prostatic, liver and pancreatic cancers. Elevated serum CEA levels have also been detected in patients with nonmalignant disease, especially patients who are older or who are smokers. CEA levels are not useful in screening the general population for undetected cancers. However, CEA levels provide important information about patient prognosis, recurrence of tumors after surgical removal, and effectiveness of therapy.

Alternative Name: Carcinoembryonic Antigen

Methodology
Chemiluminescent Microparticle immunoassay (CMIA)
Specimen Required

SST. Volume 1 (0.5) mL serum. Stability: Ambient – 5 Day, Refrigerated – 7 Days, Frozen – 2 Months

CPT Code(s)
82378